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Introduction: We expanded upon our previous experience using involved-field fraction-
ated radiotherapy (IFRT) as an alternative to whole brain radiotherapy or stereotactic
radiosurgery for patients with surgically resected brain metastases (BM).
Materials and methods: All patients with single BM who underwent surgical resection
followed by IFRT at our institution from 2006 to 2013 were evaluated. Local recurrence
(LR)-free survival, distant failure (DF)-free survival, and overall survival (OS) were deter-
mined. Analyses were performed associating clinical variables with LR and DF. Salvage
approaches and toxicity of treatment for each patient were also assessed.
Results:Median follow-upwas 19.1months. Fifty-six patients were treated with amedian
dose of 40.05Gy/15 fractions with IFRT to the resection cavity. LR-free survival was
91.4%, DF-free survival was 68.4%, and OS was 77.7% at 12months. No variables
were associated with increased LR; however, melanoma histopathology and infraten-
torial location were associated with DF on multivariate analysis. LRs were salvaged
in 5/8 patients, and DFs were salvaged in 24/29 patients. Two patients developed
radionecrosis.
Conclusion: Adjuvant IFRT is feasible and safe for well-selected patients with surgically
resected single BM. Acceptable rates of local control and salvage of distal intracranial
recurrences continue to be achieved with continued follow-up.
Keywords: involved-field fractionated radiotherapy, stereotactic radiosurgery, brain metastases, surgical
resection
Introduction
Brain metastases (BM) are the most common central nervous system (CNS) tumors in adults
(1, 2). Prognosis is poor according to a recursive partitioning analysis (RPA) estimating a median
survival of 2.3–7.1months for patients treated with whole brain radiotherapy (WBRT) (3). Some
patients live longer, as demonstrated by a graded prognostic assessment based on tumor pathology,
estimating median survival as high as 18.7months for patients with limited risk factors (4). A
nomogram was developed to provide individualized estimates of survival (5). In the breast cancer
Frontiers in Oncology | www.frontiersin.org September 2015 | Volume 5 | Article 2061
Shin et al. IFRT post-resection of single brain metastases
population, a recently validated modified breast graded prog-
nostic assessment demonstrated improvement in overall survival
(OS) in patients with 3 BM compared to >3 BM. The best
estimated median OS in patients with favorable risk factors using
this index was as high as 28.8months (6). Despite these tools,
it is still difficult to accurately predict the survival of individual
patients with BM as some patients survive years after treatment
(7). Improvements in systemic therapy and understanding of
tumor biologymay further improve the outlook of this population,
with an increasing emphasis on enhancing quality of life after
treatment (8, 9).
Therapeutic options for BM include corticosteroids, surgery,
WBRT, and stereotactic radiosurgery (SRS). Two phase three
randomized trials demonstrated decreased LR and improved OS
and quality of life for patients with single BM treated with surgery
combined with WBRT compared to WBRT alone (10, 11). The
importance of WBRT following surgery was demonstrated in a
separate randomized trial, showing that WBRT decreases the risk
of LR, DF, and neurologic death, with no improvement in OS or
functional independence (12).
These outcomes justify use of WBRT following surgical resec-
tion of single BM; however, these benefits come at the cost of
late neurocognitive side effects. Due to improvements in systemic
therapy, patients can live to experience the late effects of WBRT,
prompting an interest in improving control of intracranial disease
while minimizing late neurocognitive effects (13–15). Treatment
with memantine and hippocampal-sparing radiotherapy tech-
niques are some strategies used to decrease neurocognitive decline
following WBRT (16, 17).
Since recurrences often occur at the surgical cavity following
metastasectomy, another approach is to treat the surgical cavity
with adjuvant radiotherapy to decrease LR while sparing the
majority of the brain. Focal approaches including SRS have been
used to improve control of intracranial disease, while decreasing
late neurocognitive toxicity following surgical resection of BM
(18–22). Another approach is to use involved-field fractionated
radiotherapy (IFRT). The purpose of this study is to expand upon
our reported experience and present the long-term outcomes
including LR, DF, and OS using IFRT in this population. We
also analyzed variables associated with LR and DF in this patient
population.
Materials and Methods
From 2006 to 2013, 56 consecutive patients with single BMunder-
went gadolinium-enhanced pre-operative magnetic resonance
imaging (MRI) or computed tomography (CT) of the brain if MRI
was contraindicated followed by surgical removal of BM followed
by IFRT. Patients who were selected for this treatment approach
had good performance status with either controlled primary
or extracranial metastatic disease. In addition to good perfor-
mance status and well-controlledmetastatic disease, patients were
selected for this treatment approach to improve pre-treatment
neurological symptoms, relievemass effect, or provide histopatho-
logical confirmation of metastatic disease. Patients underwent
post-operative MRI within 48 h to confirm extent of surgery. This
study was approved by our institutional review board.
Radiotherapy Planning and Treatment
Prior to radiotherapy, CT simulation was performed. Patients
were immobilized using a thermoplastic head mask, and 1.25mm
axial CT images were obtained using a LightSpeed RT 16 CT
Simulator (GE Healthcare, Waukesha, WI, USA). The images
were transferred to the Eclipse treatment planning system (Varian,
Palo Alto, CA, USA) and registered with the pre-operative T1-
weighted pre and post-contrast and T2-weighted MRI to aid in
target delineation. In patients who were unable to undergo MRI
examination due to contraindications (i.e., presence of a cardiac
pacemaker), the CT simulation images were registered with the
pre-operative pre- and post-contrast CT of the brain.
The surgical resection cavity was identified on planning CT,
and was defined as the clinical target volume (CTV). Substantial
collapse of the surgical cavity identified on post-operative MRI
or CT brain was treated with SRS. The planning target volume
(PTV) was defined as a 10mm isometric margin around the
CTV (23). Radiotherapy was planned to a dose of 30–40.05Gy
in 10–15 fractions prescribed so that 100% of the PTV received
95% of the dose. The rationale for using this dose is based on
its biological equivalence to a dose of 36Gy/12 fractions used
in a study conducted by Patchell et al., assuming an α/β ratio
of 2 for CNS tissue and 10 for brain tumor (10). Treatment was
delivered using a Varian Clinac 21EX or 2100c linear accelerator
(Varian, Palo Alto, CA, USA) with three-dimensional conformal
or intensity-modulated radiotherapy using 4MV/6MV photons.
Follow-Up
Patients had clinical and radiologic follow-up with neurological
examination andMRI scans 1month after completion of IFRT and
every 3months thereafter.
Data Collection
All patients with single BM who underwent surgery followed
by IFRT from 2006 to 2013 were identified by reviewing the
clinical charts of patients treated in our department, with patient
characteristics collected and recorded in a database.
Statistical Analysis
Clinical endpoints include LR, defined as the presence of new
enhancement along the resection cavity identified on serial MRI,
and DF, defined as enhancement consistent with BM and/or
leptomeningeal spread outside the IFRT volume. Time to local
or distant progression was defined from the date of surgery to
the first MRI demonstrating recurrence. OS was calculated from
date of BM diagnosis until date of death. Parameters associated
with LR and/or DF were assessed including active extracranial
disease, histopathology of primary tumor [non-small cell lung
cancer (NSCLC), breast, or melanoma], tumor maximal diame-
ter (<3 cm or 3 cm), en bloc versus piecemeal surgical resec-
tion, lesion location (infratentorial versus supratentorial), and
tumor depth (superficial with dural involvement versus deep
parenchymal invasion). Statistical analysis was performed using
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SPSS software (version 20.0, IBM, Armonk, NY, USA). The
Kaplan–Meier method was used to calculate the rate of OS, LR-
free survival, and DF-free survival. Univariate and multivariate
analyses of significance were performed using Cox regression
analysis. A p-value of 0.05 or less was considered statistically
significant.
Results
Fifty-six patients with single BMwho underwent surgery followed
by IFRT were included in this study. Detailed characteristics
of the study group are shown in Table 1. Forty-seven (84%)
presented with neurological symptoms, and seven presented
without neurological symptoms identified incidentally on brain
imaging.
Surgical Treatment Characteristics
All 56 patients underwent gross total resection (GTR), with 27
(48%) having their BM removed en bloc and 29 (52%) with piece-
meal resection. The most common tumor histopathology was
NSCLC in 20 (36%), breast cancer in 15 (27%), and melanoma
TABLE 1 | Patient characteristics.
Characteristics n=56 %
Gender
Men 19 33.9
Women 37 66.1
Age (years)
Median (range) 58 (range: 27–82)
RPA class
I 21 37.5
II 34 60.7
III 1 1.8
KPS score
60 1 1.8
70 4 7.1
80 16 28.6
90 35 62.5
Median (range) 90 (range: 60–90)
Extracranial metastases
Present 28 50.0
Absent 28 50.0
Primary cancer
NSCLC 20 35.6
Breast 15 26.8
Melanoma 11 19.6
Unknown 3 5.4
Ovary 3 5.4
Gastric 1 1.8
Bladder 1 1.8
Sarcoma 1 1.8
Endometrium 1 1.8
Tumor size (cm)
Mean (range) 3.4 (range: 1.7–5.7)
Tumor location
Cerebellum 17 30.3
Frontal 11 19.6
Parietal 10 17.9
Temporal 9 16.1
Occipital 8 14.3
Thalamus 1 1.8
in 11 patients (20%). Thirty-eight (68%) had supratentorial
lesions, while 18 (32%) had infratentorial lesions. Seventeen
(30%) had superficial lesions (involvement/abutment of dura)
and 39 (70%) had deep lesions (surrounded by parenchyma).
Mean tumor size (tumormaximal dimension determined byMRI)
was 3.4 cm (range, 1.7–6 cm), with 35/56 having tumors 3 cm
in size.
Radiotherapy Characteristics
Median time to start radiotherapy following surgery was 29 days
(range, 4–107 days). Surgical cavity volume was contoured as a
CTV using CT simulation image registered with post-operative
MRI. The median volume of the post-operative cavity in all
patients was 15 cm3 (range, 3.8–93.3 cm3). Patients were treated
with radiotherapy to a median dose of 40.05Gy/15 daily frac-
tions over 3weeks at 2.67Gy per fraction (range, 30–40.05Gy in
10–15 fractions) (Figure 1). The majority (51/56) were treated to
40.05Gy/15 fractions.
Systemic Therapy
Thirty-nine of 56 (70%) received systemic anti-neoplastic therapy,
with 22 starting treatment prior to their course of IFRT and 17
starting systemic therapy following completion of IFRT. None
received systemic anti-neoplastic therapy concurrently with IFRT.
Local Recurrence
Median follow-up was 19.1months (range, 1.8–93.9months),
with local control achieved in 48 (85.7%). Actuarial rates of
LR-free survival at 12 and 24months were 91.4 and 85.1%,
respectively, 95% CI [not reached] (Figure 2). Univariate Cox
regression analysis demonstrated no clinical variables associated
with increased incidence of LR including, NSCLC histopathology
(p= 0.52), tumor maximal diameter 3 cm (p= 0.78), piecemeal
resection of tumor (p= 0.41), and superficial tumor depth with
involvement of dura mater (p= 0.73).
FIGURE 1 | Treatment planning following GTR of single BM. (A)
Pre-operative MRI (T1 post). (B) Post-operative MRI fused with planning CT
for treatment planning (magenta=CTV, yellow= 100% isodose line,
green= 95% isodose line, blue= 90% isodose line).
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FIGURE 2 | Kaplan–Meier analysis of local recurrence-free survival at
the surgical bed.
Distant Failure
Distant failure was observed in 29 (51.8%), and actuarial rates
of DF-free survival at 12 and 24months were 68.4 and 45.7%,
respectively, 95% CI (10.1–31.1) (Figure 3). Univariate analyses
of all clinical variables demonstrated that melanoma histopathol-
ogy [p= 0.03, hazard ratio (HR)= 2.46, 95% CI (1.06–5.74)] and
infratentorial location [p= 0.02, HR= 2.51, 95% CI (1.15–5.49)]
were associated with increased incidence of DF. Melanoma
histopathology [p= 0.02, HR= 2.70, 95% CI (1.16–6.28)] and
infratentorial location [p= 0.03, HR= 2.70, 95% CI (1.23–5.91)]
continued to be associated withDF onmultivariate analyses. Thir-
teen of 29 (45%)who developedDFhad infratentorial tumors, and
5/10who presentedwith leptomeningeal spread had infratentorial
tumors.
Leptomeningeal Spread
Following IFRT, 10/56 (18%) developed leptomeningeal spread.
Five had single BM located in the posterior fossa, and three had
BM superficial in location. Histopathology was not significantly
associated with increased risk of leptomeningeal spread.
Intracranial Patterns of Failure
Patterns of intracranial failure were recorded, with 3 (5%) having
LR, 21 (38%) having DF, and 5 (9%) having both LR and DF.
FIGURE 3 | Kaplan–Meier analysis of distant failure-free survival in
the CNS.
Overall Survival
At most recent follow-up, 69.1% of patients were alive. Survival
was not significantly associated with RPA class. Median survival
was 19.1months (range, 2–94months). Twelve and 24-month OS
rates were 77.7 and 61.1%, respectively (figure not shown). Of all
patients who died, three died of neurologic death from progres-
sion of intracranial disease, seven died of death due to progression
of extracranial disease, one died of natural cause unrelated to
malignancy, and six died of unknown cause.
Salvage Treatment
LR were salvaged in four patients – two with surgery and SRS, one
with SRS, and one with surgery and WBRT. DF were salvaged in
24 patients – 16 patients with SRS, three with WBRT, two with a
second course of IFRT, two with chemotherapy and IFRT, and one
with chemotherapy alone.
Complications of Treatment
Two presented with grade 2 adverse effects of treatment with
CNS necrosis [CTCAE Version 4.0]. One patient with diagnosis
of BRAF mutated metastatic melanoma, developed symptomatic
radiation effect with headaches 2 years following her course of
IFRT to 40.05Gy/15 fractions as seen on brain MRI, with exten-
sive confluent FLAIR and T2-weighted hyperintensity, but no
evidence of disease progression in the area of prior radiation treat-
ment. Her symptoms are presently being managed with steroids,
at a dose of 40mg daily. Another patient with NSCLC, initially
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treated with IFRT to 40.05Gy/15 fractions, developed histolog-
ically confirmed radionecrosis that was initially thought to be a
LR on surgical resection following salvage treatment of distant
BM with SRS. Late neurocognitive effects of treatment were not
systematically recorded in the medical record.
Discussion
We report the only series using IFRT following surgical resec-
tion of single BM in 56 patients with a median follow-up of
19.1months, expanded from our previous series of 33 patients
(23). A 12-month local control rate of 91.4% is consistent with
results reported by the Patchell study (90%), and compares favor-
ably with other series of focal treatments with 12-month local con-
trol rates ranging from 74 to 94% (18–22, 24–30) (Table 2). The
12-month DF rate in our series was 32.6%, which compares favor-
ably with other series ranging from 28 to 69% (18–22, 24, 25, 27–
30) (Table 2). These favorable resultsmay be due to improvements
in anti-neoplastic therapy in addition to good performance status
and well-controlled systemic disease. However, with continued
follow-up, 51.8% of patients developed DF.
With comparable rates of local control, SRS and brachytherapy
have advantages compared to IFRT with respect to treatment
duration. In our series, IFRT was delivered predominantly over
3weeks, in contrast to SRS and brachytherapy, which can be deliv-
ered in a single day. The disadvantages of brachytherapy include
risk of infection, limited availability, and operator experience (31).
The primary disadvantage of SRS is difficulty of target volume
identification following collapse of the surgical cavity. Addition-
ally, removal of larger tumors (3 cm) may leave a surgical cavity
too large for safe delivery of single-fraction SRS (18, 22, 24, 25,
29). The primary arguments in favor of IFRT include ease of
defining PTV, reproducible treatment planning, and treatment of
tumor resection sites too large for single-fraction SRS. Alterna-
tively, multi-dose SRS has been proposed as a treatment option for
patients with large tumor resection cavities (3 cm); however, this
may come at a cost of either decreased local control or increased
risk of adverse treatment effects. In a series of 101 patients with a
median surgical cavity volume of 17.5 cm3, patients were treated
with a multi-dose SRS regimen of 27Gy in three fractions, result-
ing in a 9% risk of radionecrosis or adverse radiation effect.
In another series with 65 patients and a median surgical cavity
volume of 8.1 cm3, treatment with multi-dose stereotactic radio-
therapy (SRT) resulted in a local control rate of 70% at 24months
(32, 33). The median surgical cavity volume in our series using
IFRT was 15 cm3, with a local control rate of 85% at 24months,
and resulting in low events of radionecrosis or adverse radiation
effect (4%). Patients presenting with larger surgical cavity volumes
will, therefore, be selected for treatment with IFRT instead of
multi-dose SRT not only to avoid increased risk of toxicity from
treating larger volume surgical cavities but also due to physician
preference.
Previously identified risk factors including larger size, involve-
ment of meninges, and surgical resection technique (piecemeal
versus en bloc) did not adversely affect local control in our series
on univariate analysis (34, 35). This is in contrast to the results of
a phase II study where tumor size 3 cm and superficial tumors
with dural/pial involvement were associated with increased LR in
patients treated with SRS following surgery (18). These discrepan-
cies may be due to larger PTVmargins (10mm) used in this study
compared to the margins (2–3mm) used in the phase II study.
Onmultivariate analysis, infratentorial location andmelanoma
histopathology were associated with DF. These risk factors are
consistent with other series using SRS following surgical resection
TABLE 2 | Selected series outcomes of different treatment options following surgical resection of brain metastases.
Author N Gross
total
resection
(%)
Adjuvant
treatment
Median
dose Gy
(range)
Median
follow-up,
months
(range)
Local
control at
12months
(%)
Local
control at
24months
(%)
DisDistant
relapse at
12months
(%)
Median
survival,
months
(range)
Radionecrosis/
adverse
radiation
effect (%)
Brennan et al. (18) 39 92 SRS 18 (15–22) 12 (1–94) 85 a 44 15 (1–94) 18
Choi et al. (25) 112 90 SRS 20 (12–30) 11 (1–87) 91 88 54 17 (2–114) 7
Do et al. (29) 30 a SRS/SRT (15–27.5) a 82 a 69 a 7
Karlovits et al. (19) 52 92 SRS 15 (8–18) 13 92 a 44 15 0
Kelly et al. (27) 18 94 SRS 18 (15–18) 13 (3–22) 89 a 35 Not reached 0
Mathieu et al. (22) 40 80 SRS 16 (11–20) 13 (2–56) 74 a 54 13 (2–56) 5
Petr et al. (20) 72 100 I-125 seeds b 16 (3–34) 93 a 32 14 0
Quigley et al. (21) 32 94 SRS 14 (10–18) 14 94 a 28 16 0
Robbins et al. (28) 85 68 SRS 16 (12–20) 11 (1–93) 81 76 58 12 8
Soltys et al. (24) 72 85 SRS 19 (15–30) 8 (0.1–81) 79 a 47 15 (1–81) 10
Minniti et al. (31) 101 72 SRSc 27 16 (6–44) 93 84 50 17 9
Ahmed et al. (32) 65 97 SRSc (20–30) 9 (1–29) 87 70 51 10 (1–30) 2
Ling et al. (30) 100 81 SRSc 22 (10–28) 12 (0.6–87) 72 a 64 13 9
Patchell et al. (10) 23 100 WBRT 36 (12 fractions) 18 (17–49) 80d a a 10 a
Patchell et al. (12) 49 100 WBRT 50.4 (28 fractions) 12 90d a 14d 12 a
Patchell et al. (12) 46 100 None 11 54d a 37d 11 a
Postop IFRT study 56 100 IFRT 40.05 (30–40.05) 19 (2–94) 91 85 33 19 (2–94) 4
aNot reported.
bActivity in mCi, not Gy.
cMulti-session SRS.
dActuarial incidence with no report at 12 or 24months.
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of BM (18, 36). The increased risk of DF in patients with infraten-
torial BM may be due its location proximal to the cerebellar cis-
terns, leading to increased seeding of the cerebrospinal fluid (37).
An association between melanoma histopathology and DF was
supported by a series of patients treated with surgical resection
followed by SRS (25). Despite this association with increased DF,
it is unclear what is the appropriate therapeutic choice for this
specific population due to the introduction of immunotherapy
and targeted therapy (38, 39).
Over half of the patients in our series developed DF with
continued follow-up. This highlights the importance of salvage
treatment options to address LR and DF. We have utilized a
variety of salvage approaches tailored to specific clinical situations,
including WBRT with or without exclusion of the prior IFRT
volume as well as SRS alone.
Although treatment was well tolerated with minimal acute and
late toxicity, one important limitation of this study is the absence
of neurocognitive testing. Another limitation of this study is the
number of patients evaluated in this study, the heterogeneity of
dose regimens used in this study (30–40.05Gy/10–15 fractions),
the lack of information regarding targetable mutations or rear-
rangements to further characterize this selected population, and
the inherent biases associated with a retrospective study. Yet, our
motivation for our treatment approach is to decrease the risk
of neurocognitive toxicity as one randomized trial demonstrated
measurable decline at 4months with SRS followed by WBRT
compared to SRS alone using the Hopkins Verbal Learning Test-
Revised (13, 15). Due to the solid theoretical and retrospective
evidence that minimizing treatment of normal brain is a worth-
while clinical goal, it will be difficult to directly compare IFRT
with WBRT in a randomized trial for patients with surgically
resected single BM.However, an interesting question is to evaluate
the effectiveness and toxicity of SRS versus IFRT in this patient
population. Another worthwhile approach may be consideration
of a tighter margins using IFRT to further spare normal brain.
In conclusion, we demonstrate feasibility and safety of using
IFRT following surgical resection of single BM for patients with
good performance status and well-controlled primary disease.
IFRT can be considered as an alternative therapeutic approach to
SRS for patients with resected metastases and surgical resection
cavities 3cm, and in lieu of WBRT for these select patients with
close follow-up.
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